Roche Accelerates Obesity Drug Development, Projects $3.6 Billion in Annual Sales

Swiss pharma giant aims to cut development costs by 20% and speed up drug timelines by 40%, targeting market leaders Novo Nordisk and Eli Lilly.

Roche has fast-tracked three obesity and diabetes drug candidates acquired from Carmot Therapeutics, aiming for a commercial launch beyond 2028.
The company projects that these drugs could generate over 3 billion Swiss francs ($3.6 billion) in annual sales.
Roche plans to reduce drug development costs by 20% and shorten the timeline from early discovery to the end of Phase 3 trials by 40% by 2030.
The obesity drug CT-388 has shown promising results, with patients losing 18.8% of their weight on average after 24 weeks in a clinical trial.
Roche's strategic push includes reallocating resources, expanding clinical trial sites, and targeting additional indications to maximize the potential of their drug pipeline.